Anthera Pharmaceuticals readies $25 million at-the-market financing

H.C. Wainwright raises funds for clinical research, corporate purposes

By Devika Patel

Knoxville, Tenn., April 22 – Anthera Pharmaceuticals, Inc. arranged a $25 million at-the-market agreement with H.C. Wainwright & Co., LLC, according to a prospectus supplement filed Friday with the Securities and Exchange Commission.

H.C. Wainwright will be paid a 3% commission.

Proceeds will be used for clinical research and development and general corporate purposes.

Anthera, based in Hayward, Calif., is a biopharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.